Align Technology/$ALGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Align Technology
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling a lion's share of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. Invisalign treats over 2 million cases annually, or roughly 10% of all orthodontic cases and has treated over 20 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
- Ticker
- $ALGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 20,290
- Headquarters
- Tempe, United States
- Website
- www.aligntech.com
Align Technology Metrics
BasicAdvanced
$11B
22.44
$6.87
1.67
-
Price and volume
Market cap
$11B
Beta
1.67
52-week high
$200.44
52-week low
$130.23
Average daily volume
996K
Financial strength
Current ratio
1.425
Quick ratio
1.207
Long term debt to equity
0.026
Total debt to equity
0.026
Profitability
EBITDA (TTM)
954.175
Gross margin (TTM)
71.34%
Net profit margin (TTM)
11.83%
Operating margin (TTM)
19.45%
Effective tax rate (TTM)
23.65%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
7.93%
Return on equity (TTM)
11.91%
Valuation
Price to earnings (TTM)
22.441
Price to revenue (TTM)
2.646
Price to book
2.54
Price to tangible book (TTM)
2.94
Price to free cash flow (TTM)
16.996
Free cash flow yield (TTM)
5.88%
Free cash flow per share (TTM)
9.068
Growth
Revenue change (TTM)
4.42%
Earnings per share change (TTM)
33.19%
3-year revenue growth (CAGR)
2.99%
10-year revenue growth (CAGR)
15.12%
3-year earnings per share growth (CAGR)
13.44%
10-year earnings per share growth (CAGR)
11.37%
What the Analysts think about Align Technology
Analyst ratings (Buy, Hold, Sell) for Align Technology stock.
Analyst projections of the future price of Align Technology stock.
Bulls say / Bears say
Clear-aligner demand is still growing: Q3 case volume rose 6.6% year on year, supported by record doctor submitters and broad international growth. North American orthodontist shipments also returned to growth after six quarters of declines. (Align Technology)
Profitability is improving even in a difficult market: Q3 non-GAAP operating margin rose 0.5 percentage points year on year to 24.4%, and management expects another 100-basis-point improvement for 2026. The company also plans about $500 million of share repurchases this year. (Align Technology)
New digital planning, AI and 3D-printing features could make Align’s platform more useful to practices and help broaden treatment options. Recent additions include AI-assisted restorative design and tools that let patients visualise potential treatment outcomes. (Align Technology)
Demand remains exposed to cautious consumers and discretionary spending: management said those conditions persisted in Q3 and expects only low-single-digit year-on-year aligner volume growth in Q4. Its 2026 revenue outlook implies modest growth of roughly 3% to 4%. (Align Technology)
Pricing and product mix are weighing on growth: Q3 clear-aligner volume rose 6.6%, but revenue increased only 4.2%, while imaging and CAD/CAM revenue fell 7.6%. Management cited lower aligner selling prices and a shift towards lower-priced scanners and flexible purchasing models. (Align Technology)
Competition-related legal risks have increased: the European Commission opened an antitrust investigation into alleged restrictions on rival scanners, and a US appeals court revived claims over Align’s past interoperability practices. Neither action establishes wrongdoing, but both could bring legal costs or pressure on its commercial practices. (MassDevice, Dental Tribune)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
Align Technology Financial Performance
Revenues and expenses
Align Technology Earnings Performance
Company profitability
Upcoming events
No upcoming events
Align Technology News
AllArticlesVideos
Funds containing Align Technology
AllUSDEURGBP
Fund name | Fund size | $ALGN weighting |
|---|---|---|
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.20% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 0.20% |
Xtrackers S&P 500 Equal Weight£XDWE | $16B | 0.19% |
Xtrackers S&P 500 Equal Weight$XDEW | $16B | 0.19% |
iShares AI Adopters and Applications€AIAA | $188M | 0.19% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.